AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +65

The Engine Behind ABBV Stock Has Real Parts | Trefis

📈 ABBV stock gained 40% over the last twelve months and is trading near its 52-week high.

💰 Operating margin reached 33%, significantly outperforming the S&P 500 median of 18.4%.

💵 Operating cash flow margin hit 34%, well above the market average of 22%.

🧬 Skyrizi sales surged 29% to $4.5 billion in the most recent quarter.

🔬 Rinvoq sales grew 20% to $2.1 billion, reinforcing the immunology franchise's strength.

📊 New data shows a Crohn's disease combination therapy could double endoscopic remission rates.

💸 P/E multiple stands at 126.3x, a stark premium to the S&P 500 median of 24.2x.

📉 Management lowered its 2026 EPS guidance range to $13.90-$14.10 from a prior forecast of $14.20.

⚠️ Intense competition in immunology and oncology poses risks to the growth narrative supporting the premium valuation.

🎯 Investors are watching execution against the revised 2026 guidance as the primary test for the business engine.

Bullish Signals
  • AbbVie achieved a 40% stock return over the last twelve months, demonstrating strong market performance.
  • The company's operating margin of 33% crushes the S&P 500 median of 18.4%, indicating superior efficiency.
  • Operating cash flow margin of 34% significantly exceeds the market average of 22%.
  • Skyrizi sales surged 29% to $4.5 billion, showing strong growth in a key blockbuster drug.
  • Rinvoq sales grew 20% to $2.1 billion, confirming continued expansion in the immunology portfolio.
  • Recent clinical data suggests a combination therapy for Crohn's disease could double endoscopic remission rates compared to monotherapy.
  • The company has successfully pivoted its immunology franchise to new blockbusters as Humira faces biosimilar competition.
Risk Factors
  • AbbVie trades at a P/E multiple of 126.3x, which is a massive premium to the S&P 500 median of 24.2x.
  • Management lowered its 2026 adjusted EPS guidance from $14.20 to a range of $13.90-$14.10.
  • The immunology and oncology sectors are described as crowded fields with relentless development pace from competitors.
  • A competitor's breakthrough or a clinical setback for a key pipeline asset could challenge the growth narrative supporting the current premium valuation.
Full Analysis
AbbVie (ABBV) stock has delivered a significant 40% return over the last twelve months, trading near its 52-week high as investors assess whether its premium valuation leaves room for future growth. The company's momentum is driven by strong operational efficiency and a successful pivot in its immunology franchise, which remains robust despite biosimilar competition affecting its legacy drug Humira. Financial metrics highlight AbbVie's strength with an operating margin of 33% compared to the S&P 500 median of 18.4%, and an operating cash flow margin of 34% versus the market average of 22%. Recent quarterly sales demonstrate this growth, with Skyrizi revenue surging 29% to $4.5 billion and Rinvoq sales increasing 20% to $2.1 billion. Despite these fundamentals, AbbVie trades at a substantial premium with a price-to-earnings multiple of 126.3 against an S&P 500 median of 24.2, and a price-to-sales multiple of 7.3 versus 3.3 for the broader market. Management has lowered its 2026 adjusted earnings per share guidance to a range of $13.90 to $14.10 from a prior forecast of $14.20, setting a critical test for investors regarding execution and valuation justification. The article notes that while the immunology space is crowded with intense competition, AbbVie's current products are leading. Future performance will depend on whether the company can meet its revised earnings targets to sustain its high valuation in a competitive environment.